← All stocks

ACCENDRA HEALTH INC/VA/

ACH No buying or selling
CIK 0000075252 #4322 in the set updated 19 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
$0.00
$0.00 against sales at will

By person

16 insiders · 0 transactions
4.9×

Edward A. Pesicka holds only 4.9 times base salary in stock. $5.70M of shares against $1.15M in salary for 2025.

Salary from the company's own proxy. The shares are what Edward A. Pesicka last reported holding, valued at $5.31, the price Common Stock was last bought or sold at on the open market here, on 14 Aug 2025.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Coliseum Capital Management, LLC entity
10% owner
13,100,807
$69.57M
+69.5%
Pesicka Edward A
President & CEO
1,072,785
$5.70M
+42.3%
Bernocchi Perry A
EVP, Chief Operating Officer
313,913
$1.67M
+142.4%
Leon Jonathan A
EVP & CFO
290,533
$1.54M
+422.4%
Long Andrew G
EVP, CEO P&HS
214,064
$1.14M
+41.3%
Galloway Heath H
EVP,General Counsel & CorpSecy
166,306
$883.08K
+213.3%
Lowry Michael Wayne
SVP, Corporate Controller
121,921
$647.40K
+26.5%
Stone Jennifer A
EVP, CHRO
110,327
$585.84K
+93.3%
Sarkar Snehashish
Chief Information Officer
108,586
$576.59K
+83.6%
Klemash Stephen W
Director
90,242
$479.19K
+199.4%
Gardner-Smith Kenneth
Director
86,113
$457.26K
+231.1%
Kline Teresa L.
Director
85,316
$453.03K
+238.4%
Henkel Robert J
Director
77,412
$411.06K
+59.6%
Beck Mark A
Director
71,259
$378.39K
+538.9%
Johnson-Mills Rita
Director
54,125
$287.40K
+114.7%
Rollins Carissa
Director
53,902
$286.22K
+115.7%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 0
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 0
History held since 1 Sep 2016